PX'Therapeutics Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
29
- Latest Deal Type
-
M&A
PX'Therapeutics General Information
Description
Developer of a biotechnology company designed to support the development of biotherapeutics. The company provides contract research, process development, and manufacturing services for recombinant proteins and monoclonal antibodies, enabling pharmaceutical and biotechnology firms to advance therapeutic candidates from early-stage research through to clinical and commercial production.
Contact Information
Website
www.px-therapeutics.comCorporate Office
- 7, parvis Louis Néel MINATEC - BHT 52 A
- Cedex 9, CS 20050
- 38040 Grenoble
- France
Corporate Office
- 7, parvis Louis Néel MINATEC - BHT 52 A
- Cedex 9, CS 20050
- 38040 Grenoble
- France
PX'Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 03-Oct-2012 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Private | 06-Feb-2008 | Completed | Generating Revenue | |||
| 2. Grant | 19-Nov-2003 | $1.52M | Completed | Startup | ||
| 1. Seed Round | 19-Nov-2003 | $1.52M | $1.52M | Completed | Startup |
PX'Therapeutics Patents
PX'Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2864549-B1 | Molecular engineering method for optimizing the expression of recombinant proteins at high and low rate. | Inactive | 31-Dec-2003 | ||
| FR-2864549-A1 | Preparation of recombinant proteins at different rates in different cells, useful e.g. for making therapeutic antibodies, based on operational integration of dna cassettes | Active | 31-Dec-2003 |
PX'Therapeutics Signals
PX'Therapeutics Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amorcage Rhone-Alpes | Venture Capital | Minority | ||
| Crédit Mutuel Equity | Growth/Expansion | Minority | ||
| Kreaxi | Venture Capital | Minority | ||
| Rhône Dauphiné Développement | Venture Capital | Minority | ||
| Rhône-Alpes Création | Venture Capital | Minority |
PX'Therapeutics FAQs
-
When was PX'Therapeutics founded?
PX'Therapeutics was founded in 2000.
-
Where is PX'Therapeutics headquartered?
PX'Therapeutics is headquartered in Grenoble, France.
-
What is the size of PX'Therapeutics?
PX'Therapeutics has 29 total employees.
-
What industry is PX'Therapeutics in?
PX'Therapeutics’s primary industry is Biotechnology.
-
Is PX'Therapeutics a private or public company?
PX'Therapeutics is a Private company.
-
What is PX'Therapeutics’s current revenue?
The current revenue for PX'Therapeutics is .
-
How much funding has PX'Therapeutics raised over time?
PX'Therapeutics has raised $1.52M.
-
Who are PX'Therapeutics’s investors?
Amorcage Rhone-Alpes, Crédit Mutuel Equity, Kreaxi, Rhône Dauphiné Développement, and Rhône-Alpes Création have invested in PX'Therapeutics.
-
When was PX'Therapeutics acquired?
PX'Therapeutics was acquired on 03-Oct-2012.
-
Who acquired PX'Therapeutics?
PX'Therapeutics was acquired by Aguettant Sante.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process